Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care: A multi-disciplinary team approach to diagnosis and management

QJM: An International Journal of Medicine

Volumn 107, Issue 1, 2014, Pages 33-41

  Armstrong, Matthew J ^a,b   Hazlehurst, Jonathan M ^a   Parker, Richard ^a,b   Koushiappi, Elena ^b   Mann, Jake ^b   Khan, Sheeba ^c   Philips, Angela ^b   Chandler, Liz ^b   Johnson, Jill ^b   Round, Maria ^b   Haydon, Geoffrey ^b   Karamat, Mohammad A ^c   Newsome, Philip N ^a,b   Tomlinson, Jeremy W ^a  

^a University of Birmingham   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASYMPTOMATIC DISEASE; CHOLESTEROL BLOOD LEVEL; CLASSIFICATION ALGORITHM; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE SEVERITY; ELASTOGRAPH; ELASTOGRAPHY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NAFLD FIBROSIS SCORE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATIENT REFERRAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SECONDARY HEALTH CARE; TRANSIENT ELASTOGRAPHY; WEIGHT REDUCTION; AGED; BIOPSY; FATTY LIVER; LIVER; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PATIENT CARE; SECONDARY CARE CENTER; SEVERITY OF ILLNESS INDEX; UNITED KINGDOM;

ADULT; AGED; BIOPSY; DIABETES MELLITUS, TYPE 2; ELASTICITY IMAGING TECHNIQUES; ENGLAND; FATTY LIVER; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; PATIENT CARE TEAM; PROSPECTIVE STUDIES; SECONDARY CARE CENTERS; SEVERITY OF ILLNESS INDEX;

EID: 84905811366     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hct198     Document Type: Article

References (25)

1. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49:608-12.
2. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363:1341-50.
3. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126:460-8.
4. Choi JH, Rhee EJ, Bae JC, Park SE, Park CY, Cho YK, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013; 44:115-20.
5. Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30:2119-21.
6. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51:444-50.
7. Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010; 105:1567-73.
8. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2:262-5.
9. Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012; 56:234-40.
10. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142:1592-609.
11. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011; 34:1139-44.
12. Leite NC, Salles GF, Araujo ALE, Villela-Nogueira CA, Cardoso CRL. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29:113-9.
13. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45:846-54.
14. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43:617-49.
15. Casey SP, Kemp WW, McLean CA, Topliss DJ, Adams LA, Roberts SK. A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. Scand J Gastroenterol 2012; 47:836-41.
16. Roulot D, Czernichow S, Le Clésiau H, Costes J-L, Vergnaud A-C, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48:606-13.
17. McCorry RB, Palaniyappan N, Chivinge A, Kaye P, James MW, Aithal GP. Development and evaluation of a nurse-led transient elastography service for the staging of hepatic fibrosis in patients with suspected chronic liver disease. QJM 2012; 105:749-54.
18. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-21.
19. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6:6.
20. World Health Organisation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: Report of a World Health Organisation/Internation Diabetes Federation consultation. Geneva, 2006.
21. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10:330-44.
22. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59:1265-9.
23. Marchesini G, Natale S, Manini R, Agostini F. Review article: the treatment of fatty liver disease associated with the metabolic syndrome. Aliment Pharmacol Ther 2005; 22(Suppl. 2):37-9.
24. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009; 49:80-6.
25. Tahrani AA, Ali A, Raymond NT, Begum S, Dubb K, Mughal S, et al. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med 2012; 186:434-41.